Targeting GRP78 and antiestrogen resistance in breast cancer

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Desantis C, Howlader N, Cronin KA, Jemal A. Breast cancer incidence rates in US women are no longer declining. Cancer Epidemiol. Biomarkers Prev.20(5),733–739 (2011).
  MedlineGoogle Scholar
• 2  Desantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA Cancer J. Clin.61(6),409–418 (2011).
  MedlineGoogle Scholar
• 3  Riggins RB, Schrecengost RS, Guerrero MS, Bouton AH. Pathways to tamoxifen resistance. Cancer Lett.256(1),1–24 (2007).
  Medline CASGoogle Scholar
• 4  Riggins RB, Bouton AH, Liu MC, Clarke R. Antiestrogens, aromatase inhibitors, and apoptosis in breast cancer. Vitam. Horm.71,201–237 (2005).
  Medline CASGoogle Scholar
• 5  Hong S, Didwania A, Olopade O, Ganschow P. The expanding use of third-generation aromatase inhibitors: what the general internist needs to know. J. Gen. Intern. Med.24(Suppl. 2),S383–S388 (2009).
  MedlineGoogle Scholar
• 6  Janicke F. Are all aromatase inhibitors the same? A review of the current evidence. Breast13(Suppl. 1),S10–S18 (2004).
  MedlineGoogle Scholar
• 7  Ingle JN, Suman VJ, Rowland KM et al. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J. Clin. Oncol.24(7),1052–1056 (2006).
  Medline CASGoogle Scholar
• 8  Perey L, Paridaens R, Hawle H et al. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of Phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann. Oncol.18(1),64–69 (2007).
  Medline CASGoogle Scholar
• 9  Clarke R, Brunner N. Acquired estrogen independence and antiestrogen resistance in breast cancer: estrogen receptor driven phenotypes? Trends Endocrinol. Metab.7(8),291–301 (1996).
  Medline CASGoogle Scholar
• 10  Cook KL, Shajahan AN, Warri A, Jin L, Hilakivi-Clarke LA, Clarke R. Glucose-regulated protein 78 controls cross-talk between apoptosis and autophagy to determine antiestrogen responsiveness. Cancer Res.72(13),3337–3349 (2012).▪▪ First report detailing role of GRP78 controling antiestrogen resistance.
  Medline CASGoogle Scholar
• 11  Clarke R, Skaar TC, Bouker KB et al. Molecular and pharmacological aspects of antiestrogen resistance. J. Steroid Biochem. Mol. Biol.76(1–5),71–84 (2001).
  Medline CASGoogle Scholar
• 12  Clarke R, Leonessa F, Welch JN, Skaar TC. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol. Rev.53(1),25–71 (2001).
  Medline CASGoogle Scholar
• 13  Bachleitner-Hofmann T, Pichler-Gebhard B, Rudas M et al. Pattern of hormone receptor status of secondary contralateral breast cancers in patients receiving adjuvant tamoxifen. Clin. Cancer Res.8(11),3427–3432 (2002).
  Medline CASGoogle Scholar
• 14  Clarke R, Liu MC, Bouker KB et al. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene22(47),7316–7339 (2003).
  Medline CASGoogle Scholar
• 15  Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J. Biol. Chem.276(13),9817–9824 (2001).
  Medline CASGoogle Scholar
• 16  Gething MJ, Sambrook J. Protein folding in the cell. Nature355(6355),33–45 (1992).
  Medline CASGoogle Scholar
• 17  Wang XZ, Harding HP, Zhang Y, Jolicoeur EM, Kuroda M, Ron D. Cloning of mammalian Ire1 reveals diversity in the ER stress responses. EMBO J.17(19),5708–5717 (1998).
  Medline CASGoogle Scholar
• 18  Kaufman RJ. Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. Genes Dev.13(10),1211–1233 (1999).
  Medline CASGoogle Scholar
• 19  Harding HP, Zhang Y, Ron D. Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature397(6716),271–274 (1999).
  Medline CASGoogle Scholar
• 20  Yoshida H, Haze K, Yanagi H, Yura T, Mori K. Identification of the cis-acting endoplasmic reticulum stress response element responsible for transcriptional induction of mammalian glucose-regulated proteins. Involvement of basic leucine zipper transcription factors. J. Biol. Chem.273(50),33741–33749 (1998).
  Medline CASGoogle Scholar
• 21  Yoshida H, Matsui T, Yamamoto A, Okada T, Mori K. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell107(7),881–891 (2001).
  Medline CASGoogle Scholar
• 22  Shen X, Ellis RE, Lee K et al. Complementary signaling pathways regulate the unfolded protein response and are required for C. elegans development. Cell107(7),893–903 (2001).
  Medline CASGoogle Scholar
• 23  Harding HP, Zeng H, Zhang Y et al. Diabetes mellitus and exocrine pancreatic dysfunction in PERK-/- mice reveals a role for translational control in secretory cell survival. Mol. Cell7(6),1153–1163 (2001).
  Medline CASGoogle Scholar
• 24  Clarke R, Cook KL, Hu R et al. Endoplasmic reticulum stress, the unfolded protein response, autophagy, and the integrated regulation of breast cancer cell fate. Cancer Res.72(6),1321–1331 (2012).▪▪ Review of the unfolded protein response, autophagy in estrogen receptor-positive breast cancer and endocrine resistance.
  Medline CASGoogle Scholar
• 25  Verfaillie T, Salazar M, Velasco G, Agostinis P. Linking ER stress to autophagy: potential implications for cancer therapy. Int. J. Cell Biol.2010,930509 (2010).
  MedlineGoogle Scholar
• 26  Davies MP, Barraclough DL, Stewart C et al. Expression and splicing of the unfolded protein response gene XBP-1 are significantly associated with clinical outcome of endocrine-treated breast cancer. Int. J. Cancer123(1),85–88 (2008).
  Medline CASGoogle Scholar
• 27  Fernandez PM, Tabbara SO, Jacobs LK et al. Overexpression of the glucose-regulated stress gene GRP78 in malignant but not benign human breast lesions. Breast Cancer Res. Treat.59(1),15–26 (2000).▪ Clinical data supporting role of GRP78 in breast tumors.
  Medline CASGoogle Scholar
• 28  Gazit G, Lu J, Lee AS. De-regulation of GRP stress protein expression in human breast cancer cell lines. Breast Cancer Res. Treat.54(2),135–146 (1999).
  Medline CASGoogle Scholar
• 29  Gomez BP, Riggins RB, Shajahan AN et al. Human X-box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines. FASEB J.21(14),4013–4027 (2007).
  Medline CASGoogle Scholar
• 30  Scriven P, Coulson S, Haines R, Balasubramanian S, Cross S, Wyld L. Activation and clinical significance of the unfolded protein response in breast cancer. Br. J. Cancer101(10),1692–1698 (2009).
  Medline CASGoogle Scholar
• 31  Gu Z, Lee RY, Skaar TC et al. Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-kappaB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780). Cancer Res.62(12),3428–3437 (2002).
  Medline CASGoogle Scholar
• 32  Fu Y, Li J, Lee AS. GRP78/BiP inhibits endoplasmic reticulum BIK and protects human breast cancer cells against estrogen starvation-induced apoptosis. Cancer Res.67(8),3734–3740 (2007).▪ First report of implicating GRP78 in endocrine independence.
  Medline CASGoogle Scholar
• 33  Reddy RK, Mao C, Baumeister P, Austin RC, Kaufman RJ, Lee AS. Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation. J. Biol. Chem.278(23),20915–20924 (2003).
  Medline CASGoogle Scholar
• 34  Zhou H, Zhang Y, Fu Y, Chan L, Lee AS. Novel mechanism of anti-apoptotic function of 78-kDa glucose-regulated protein (GRP78): endocrine resistance factor in breast cancer, through release of B-cell lymphoma 2 (BCL-2) from BCL-2-interacting killer (BIK). J. Biol. Chem.286(29),25687–25696 (2011).
  Medline CASGoogle Scholar
• 35  Crawford AC, Riggins RB, Shajahan AN, Zwart A, Clarke R. Co-inhibition of BCL-W and BCL2 restores antiestrogen sensitivity through BECN1 and promotes an autophagy-associated necrosis. PLoS ONE5(1),e8604 (2010).
  MedlineGoogle Scholar
• 36  He C, Klionsky DJ. Regulation mechanisms and signaling pathways of autophagy. Ann. Rev. Genet.43,67–93 (2009).
  Medline CASGoogle Scholar
• 37  Cook KL, Shajahan AN, Clarke R. Autophagy and endocrine resistance in breast cancer. Expert Rev. Anticancer Ther.11(8),1283–1294 (2011).
  Medline CASGoogle Scholar
• 38  Samaddar JS, Gaddy VT, Duplantier J et al. A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance. Mol. Cancer Ther.7(9),2977–2987 (2008).
  Medline CASGoogle Scholar
• 39  Schoenlein PV, Periyasamy-Thandavan S, Samaddar JS, Jackson WH, Barrett JT. Autophagy facilitates the progression of ERalpha-positive breast cancer cells to antiestrogen resistance. Autophagy5(3),400–403 (2009).
  Medline CASGoogle Scholar
• 40  Clarke R, Shajahan AN, Riggins RB et al. Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells. J. Steroid Biochem. Mol. Biol.114(1–2),8–20 (2009).
  Medline CASGoogle Scholar
• 41  Hoyer-Hansen M, Bastholm L, Szyniarowski P et al. Control of macroautophagy by calcium, calmodulin-dependent kinase kinase-beta, and Bcl-2. Mol. Cell25(2),193–205 (2007).
  MedlineGoogle Scholar
• 42  Hoyer-Hansen M, Jaattela M. Connecting endoplasmic reticulum stress to autophagy by unfolded protein response and calcium. Cell Death Differ.14(9),1576–1582 (2007).
  Medline CASGoogle Scholar
• 43  Li J, Ni M, Lee B, Barron E, Hinton DR, Lee AS. The unfolded protein response regulator GRP78/BiP is required for endoplasmic reticulum integrity and stress-induced autophagy in mammalian cells. Cell Death Differ.15(9),1460–1471 (2008).
  Medline CASGoogle Scholar
• 44  Bennett HL, Fleming JT, O‘prey J, Ryan KM, Leung HY. Androgens modulate autophagy and cell death via regulation of the endoplasmic reticulum chaperone glucose-regulated protein 78/BiP in prostate cancer cells. Cell Death Dis.1,e72 (2010).
  Medline CASGoogle Scholar
• 45  Cook KL, Clarke R. Heat shock 70 kDa protein 5/glucose-regulated protein 78 ‘AMP‘ing up autophagy. Autophagy8(12),1827–1829 (2012).
  Medline CASGoogle Scholar
• 46  Hoyer-Hansen M, Jaattela M. AMP-activated protein kinase: a universal regulator of autophagy? Autophagy3(4),381–383 (2007).
  MedlineGoogle Scholar
• 47  Grkovic S, O‘reilly VC, Han S, Hong M, Baxter RC, Firth SM. IGFBP-3 binds GRP78, stimulates autophagy and promotes the survival of breast cancer cells exposed to adverse microenvironments. Oncogene32(19),2412–2420 (2012).
  MedlineGoogle Scholar
• 48  Li C, Harada A, Oh Y. IGFBP-3 sensitizes antiestrogen-resistant breast cancer cells through interaction with GRP78. Cancer Lett.325(2),200–206 (2012).
  Medline CASGoogle Scholar
• 49  Cook KL, Metheny-Barlow LJ, Tallant EA, Gallagher PE. Angiotensin-(1–7) reduces fibrosis in orthotopic breast tumors. Cancer Res.70(21),8319–8328 (2010).
  Medline CASGoogle Scholar
• 50  Diop-Frimpong B, Chauhan VP, Krane S, Boucher Y, Jain RK. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc. Natl Acad. Sci. USA108(7),2909–2914 (2011).
  Medline CASGoogle Scholar
• 51  Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure – an obstacle in cancer therapy. Nat. Rev. Cancer4(10),806–813 (2004).
  Medline CASGoogle Scholar
• 52  Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene29(34),4741–4751 (2010).
  Medline CASGoogle Scholar
• 53  Kalluri R. EMT. when epithelial cells decide to become mesenchymal-like cells. J. Clin. Invest.119(6),1417–1419 (2009).
  Medline CASGoogle Scholar
• 54  Zhou C, Nitschke AM, Xiong W et al. Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype. Breast Cancer Res.10(6),R105 (2008).
  MedlineGoogle Scholar
• 55  Hiscox S, Jiang WG, Obermeier K et al. Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. Int. J. Cancer118(2),290–301 (2006).
  Medline CASGoogle Scholar
• 56  Li H, Song H, Luo J, Liang J, Zhao S, Su R. Knockdown of glucose-regulated protein 78 decreases the invasion, metalloproteinase expression and ECM degradation in hepatocellular carcinoma cells. J. Exp. Clin. Cancer Res.31,39 (2012).
  MedlineGoogle Scholar
• 57  Su R, Li Z, Li H et al. GRP78 promotes the invasion of hepatocellular carcinoma. BMC Cancer10,20 (2010).
  MedlineGoogle Scholar
• 58  Dong D, Ni M, Li J et al. Critical role of the stress chaperone GRP78/BiP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development. Cancer Res.68(2),498–505 (2008).▪ First report of GRP78 promoting angiogenesis supporting the role of GRP78 in the tumor microenvironment.
  Medline CASGoogle Scholar
• 59  Dong D, Stapleton C, Luo B et al. A critical role for GRP78/BiP in the tumor microenvironment for neovascularization during tumor growth and metastasis. Cancer Res.71(8),2848–2857 (2011).
  Medline CASGoogle Scholar
• 60  Lee AS. GRP78 induction in cancer: therapeutic and prognostic implications. Cancer Res.67(8),3496–3499 (2007).
  Medline CASGoogle Scholar
• 61  Nakagawa H, Yamamoto D, Kiyozuka Y et al. Effects of genistein and synergistic action in combination with eicosapentaenoic acid on the growth of breast cancer cell lines. J. Cancer Res. Clin. Oncol.126(8),448–454 (2000).
  Medline CASGoogle Scholar
• 62  Zhou Y, Lee AS. Mechanism for the suppression of the mammalian stress response by genistein, an anticancer phytoestrogen from soy. J. Natl Cancer Instit.90(5),381–388 (1998).
  Medline CASGoogle Scholar
• 63  Ermakova SP, Kang BS, Choi BY et al. (-)-Epigallocatechin gallate overcomes resistance to etoposide-induced cell death by targeting the molecular chaperone glucose-regulated protein 78. Cancer Res.66(18),9260–9269 (2006).
  Medline CASGoogle Scholar
• 64  Matsuo J, Tsukumo Y, Sakurai J et al. Preventing the unfolded protein response via aberrant activation of 4E-binding protein 1 by versipelostatin. Cancer Sci.100(2),327–333 (2009).
  Medline CASGoogle Scholar
• 65  Park HR, Chijiwa S, Furihata K, Hayakawa Y, Shin-Ya K. Relative and absolute configuration of versipelostatin, a down-regulator of molecular chaperone GRP78 expression. Org. Lett.9(8),1457–1460 (2007).
  Medline CASGoogle Scholar
• 66  Park HR, Tomida A, Sato S et al. Effect on tumor cells of blocking survival response to glucose deprivation. J. Natl Cancer Inst.96(17),1300–1310 (2004).
  Medline CASGoogle Scholar
• 67  Zhao P, Ueda JY, Kozone I et al. New glycosylated derivatives of versipelostatin, the GRP78/Bip molecular chaperone down-regulator, from Streptomyces versipellis 4083-SVS6. Org. Biomol. Chem.7(7),1454–1460 (2009).
  Medline CASGoogle Scholar
• 68  Umeda Y, Chijiwa S, Furihata K et al. Prunustatin A, a novel GRP78 molecular chaperone down-regulator isolated from Streptomyces violaceoniger. J. Antibiotic58(3),206–209 (2005).
  Medline CASGoogle Scholar
• 69  Umeda Y, Furihata K, Sakuda S et al. Absolute structure of prunustatin A, a novel GRP78 molecular chaperone down-regulator. Org. Lett.9(21),4239–4242 (2007).
  Medline CASGoogle Scholar
• 70  May KL, Paton JC, Paton AW. Escherichia coli subtilase cytotoxin induces apoptosis regulated by host Bcl-2 family proteins Bax/Bak. Infect. Immun.78(11),4691–4696 (2010).
  Medline CASGoogle Scholar
• 71  Paton AW, Beddoe T, Thorpe CM et al. AB5 subtilase cytotoxin inactivates the endoplasmic reticulum chaperone BiP. Nature443(7111),548–552 (2006).
  Medline CASGoogle Scholar
• 72  Paton AW, Paton JC. Escherichia coli subtilase cytotoxin. Toxins2(2),215–228 (2010).
  Medline CASGoogle Scholar
• 73  Ray R, De Ridder GG, Eu JP, Paton AW, Paton JC, Pizzo SV. The Escherichia coli subtilase cytotoxin A subunit specifically cleaves cell-surface GRP78 protein and abolishes COOH-terminal-dependent signaling. J. Biol. Chem.287(39),32755–32769 (2012).
  Medline CASGoogle Scholar
• 74  Dent P, Yacoub A, Grant S, Curiel DT, Fisher PB. MDA-7/IL-24 regulates proliferation, invasion and tumor cell radiosensitivity: a new cancer therapy? J. Cell. Biochem.95(4),712–719 (2005).
  Medline CASGoogle Scholar
• 75  Gupta P, Walter MR, Su ZZ et al. BiP/GRP78 is an intracellular target for MDA-7/IL-24 induction of cancer-specific apoptosis. Cancer Res.66(16),8182–8191 (2006).
  Medline CASGoogle Scholar
• 76  Trondl R, Heffeter P, Jakupec M, Berger W, Keppler B. NKP-1339, a first-in-class anticancer drug showing mild side effects and activity in patients suffering from advanced refractory cancer. BMC Pharmacol. Toxicol.13(Suppl 1),A82 (2012).
  Google Scholar
• 77  Groessl M, Hartinger CG. Anticancer metallodrug research analytically painting the ‘omics‘ picture-current developments and future trends. Anal. Bioanal. Chem.405(6),1791–1808 (2013).
  Medline CASGoogle Scholar
• 78  Yamazaki H, Hiramatsu N, Hayakawa K et al. Activation of the Akt-NF-kappaB pathway by subtilase cytotoxin through the ATF6 branch of the unfolded protein response. J. Immunol.183(2),1480–1487 (2009).
  Medline CASGoogle Scholar
• 79  Yahiro K, Morinaga N, Moss J, Noda M. Subtilase cytotoxin induces apoptosis in HeLa cells by mitochondrial permeabilization via activation of Bax/Bak, independent of C/EBF-homologue protein (CHOP), Ire1alpha or JNK signaling. Microb. Pathog.49(4),153–163 (2010).
  Medline CASGoogle Scholar
• 80  Yahiro K, Satoh M, Morinaga N et al. Identification of subtilase cytotoxin (SubAB) receptors whose signaling, in association with SubAB-induced BiP cleavage, is responsible for apoptosis in HeLa cells. Infect. Immun.79(2),617–627 (2011).
  Medline CASGoogle Scholar
• 81  Nakajima S, Hiramatsu N, Hayakawa K et al. Selective abrogation of BiP/GRP78 blunts activation of NF-kappaB through the ATF6 branch of the UPR. involvement of C/EBPbeta and mTOR-dependent dephosphorylation of Akt. Mol. Cell. Biol.31(8),1710–1718 (2011).
  Medline CASGoogle Scholar
• 82  Yahiro K, Morinaga N, Satoh M et al. Identification and characterization of receptors for vacuolating activity of subtilase cytotoxin. Mol. Microbiol.62(2),480–490 (2006).
  Medline CASGoogle Scholar
• 83  Arap MA, Lahdenranta J, Mintz PJ et al. Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands. Cancer Cell6(3),275–284 (2004).
  Medline CASGoogle Scholar
• 84  Kim Y, Lillo AM, Steiniger SC et al. Targeting heat shock proteins on cancer cells: selection, characterization, and cell-penetrating properties of a peptidic GRP78 ligand. Biochemistry45(31),9434–9444 (2006).
  Medline CASGoogle Scholar
• 85  Schwarze S, Rangnekar VM. Targeting plasma membrane GRP78 for cancer growth inhibition. Cancer Biol. Ther.9(2),153–155 (2010).
  Medline CASGoogle Scholar
• 86  Rosenes Z, Mulhern TD, Hatters DM et al. The anti-cancer IgM monoclonal antibody PAT-SM6 binds with high avidity to the unfolded protein response regulator GRP78. PLoS ONE7(9),e44927 (2012).
  Medline CASGoogle Scholar
• 87  Cao Y, Chen A, An SS, Ji RW, Davidson D, Llinas M. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J. Biol. Chem.272(36),22924–22928 (1997).
  Medline CASGoogle Scholar
• 88  Davidson DJ, Haskell C, Majest S et al. Kringle 5 of human plasminogen induces apoptosis of endothelial and tumor cells through surface-expressed glucose-regulated protein 78. Cancer Res.65(11),4663–4672 (2005).
  Medline CASGoogle Scholar
• 89  Zhang D, Kaufman PL, Gao G, Saunders RA, Ma JX. Intravitreal injection of plasminogen kringle 5, an endogenous angiogenic inhibitor, arrests retinal neovascularization in rats. Diabetologia44(6),757–765 (2001).
  Medline CASGoogle Scholar
• 90  Misra UK, Gonzalez-Gronow M, Gawdi G, Hart JP, Johnson CE, Pizzo SV. The role of GRP78 in alpha 2-macroglobulin-induced signal transduction. Evidence from RNA interference that the low density lipoprotein receptor-related protein is associated with, but not necessary for, GRP 78-mediated signal transduction. J. Biol. Chem.277(44),42082–42087 (2002).
  Medline CASGoogle Scholar
• 91  Mcfarland BC, Stewart J Jr, Hamza A et al. Plasminogen kringle 5 induces apoptosis of brain microvessel endothelial cells: sensitization by radiation and requirement for GRP78 and LRP1. Cancer Res.69(13),5537–5545 (2009).
  Medline CASGoogle Scholar
• 92  Lee AS. The Par-4-GRP78 TRAIL, more twists and turns. Cancer Biol. Ther.8(22),2103–2105 (2009).
  MedlineGoogle Scholar
• 93  Burikhanov R, Zhao Y, Goswami A, Qiu S, Schwarze SR, Rangnekar VM. The tumor suppressor Par-4 activates an extrinsic pathway for apoptosis. Cell138(2),377–388 (2009).
  Medline CASGoogle Scholar
• 94  Burikhanov R, Shrestha-Bhattarai T, Qiu S et al. Novel mechanism of apoptosis resistance in cancer mediated by extracellular Par-4. Cancer Res.73(2),1011–1019 (2013).
  Medline CASGoogle Scholar
• 101  Clinical trial indentification number: NCT01415297. http://clinicaltrials.gov/show/NCT01415297
  Google Scholar
• 102  Clinical trial identification number: NCT01727778. www.clinicaltrials.gov/ct2/show/NCT01727778
  Google Scholar